Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
AstraZeneca
Merck
Harvard Business School
Medtronic

Last Updated: May 27, 2022

Investigational Drug Information for Veliparib


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Veliparib?

Veliparib is an investigational drug.

There have been 96 clinical trials for Veliparib. The most recent clinical trial was a Phase 3 trial, which was initiated on April 10th 2014.

The most common disease conditions in clinical trials are Carcinoma, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).

There are three hundred and fifty-five US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for Veliparib
TitleSponsorPhase
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerAbbViePhase 1
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)AHS Cancer Control AlbertaPhase 2
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast CancerFudan UniversityPhase 2

See all Veliparib clinical trials

Clinical Trial Summary for Veliparib

Top disease conditions for Veliparib
Top clinical trial sponsors for Veliparib

See all Veliparib clinical trials

US Patents for Veliparib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Veliparib See Plans and Pricing Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA) See Plans and Pricing
Veliparib See Plans and Pricing Remote loading of sparingly water-soluble drugs into lipid vesicles ZONEONE PHARMA, INC. (San Francisco, CA) See Plans and Pricing
Veliparib See Plans and Pricing Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (Grand Cayman, KY) See Plans and Pricing
Veliparib See Plans and Pricing Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH) See Plans and Pricing
Veliparib See Plans and Pricing Bridged bicyclic nucleosides MIRAGEN THERAPEUTICS, INC. (Boulder, CO) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Veliparib

Drugname Country Document Number Estimated Expiration Related US Patent
Veliparib European Patent Office EP3131552 2034-04-16 See Plans and Pricing
Veliparib Spain ES2823756 2034-04-16 See Plans and Pricing
Veliparib Japan JP2017514806 2034-04-16 See Plans and Pricing
Veliparib Japan JP2019070012 2034-04-16 See Plans and Pricing
Veliparib Japan JP2021059548 2034-04-16 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
AstraZeneca
Merck
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.